---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-005070"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2024-07-26T23:59:59+00:00"
generated_at: "2026-05-31T15:58:42.781208+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CNS Pharma enters $5.2M ATM offering with A.G.P.; warrants repriced

## Summary
- Entered Sales Agreement with A.G.P. for at-the-market offering of up to $5.2M common stock; commission 3.0%.
- Net proceeds to be used for working capital and general corporate purposes.
- Waiver from Feb 2024 investor lifts restrictions on ATM; warrant exercise prices reduced.
- Effective Aug 1, 2024, exercise price of 587,028 Series A/B warrants lowered to Minimum Price.
- Additional 3,263,000 warrants repricing subject to shareholder approval; proxy statement due within 60 days.

## SEC filing metadata
- accession: 0001683168-24-005070
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2024-07-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316824005070/0001683168-24-005070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316824005070/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-005070
- JSON: https://secwatch.observer/filing/0001683168-24-005070.json
- Plain text: https://secwatch.observer/filing/0001683168-24-005070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.